CARISMA THERAPEUTICS INC (CARM) Stock Price, Quote, News and Overview
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
CARM Quote, Performance and Key Statistics
0.2497
+0.05 (+23.68%)
The current stock price of CARM is 0.2497 USD. In the past month the price increased by 29.98%. In the past year, price decreased by -84.59%.
CARM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About CARM
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Company Info
CARISMA THERAPEUTICS INC
3675 Market Street, Suite 401
PHILADELPHIA PENNSYLVANIA US
Employees: 46
Phone: 12674916422
CARISMA THERAPEUTICS INC / CARM FAQ
What is the stock price of CARISMA THERAPEUTICS INC today?
The current stock price of CARM is 0.2497 USD. The price increased by 23.68% in the last trading session.
What is the ticker symbol for CARISMA THERAPEUTICS INC stock?
The exchange symbol of CARISMA THERAPEUTICS INC is CARM and it is listed on the Nasdaq exchange.
On which exchange is CARM stock listed?
CARM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARISMA THERAPEUTICS INC stock?
9 analysts have analysed CARM and the average price target is 1.02 USD. This implies a price increase of 308.49% is expected in the next year compared to the current price of 0.2497. Check the CARISMA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARISMA THERAPEUTICS INC worth?
CARISMA THERAPEUTICS INC (CARM) has a market capitalization of 10.43M USD. This makes CARM a Nano Cap stock.
How many employees does CARISMA THERAPEUTICS INC have?
CARISMA THERAPEUTICS INC (CARM) currently has 46 employees.
What are the support and resistance levels for CARISMA THERAPEUTICS INC (CARM) stock?
CARISMA THERAPEUTICS INC (CARM) has a support level at 0.25 and a resistance level at 0.34. Check the full technical report for a detailed analysis of CARM support and resistance levels.
Is CARISMA THERAPEUTICS INC (CARM) expected to grow?
The Revenue of CARISMA THERAPEUTICS INC (CARM) is expected to decline by -21.05% in the next year. Check the estimates tab for more information on the CARM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARISMA THERAPEUTICS INC (CARM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CARM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CARM, evaluating the profitability, health, valuation and growth aspects
- CARISMA THERAPEUTICS INC (CARM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARISMA THERAPEUTICS INC (CARM) Sales and EPS estimates to see what analysts future expectations are.
- CARISMA THERAPEUTICS INC (CARM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARISMA THERAPEUTICS INC (CARM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARISMA THERAPEUTICS INC (CARM) Stock Chart to make your own analysis
- CARISMA THERAPEUTICS INC (CARM) Latest news and press-releases to stay up to date.
Does CARISMA THERAPEUTICS INC (CARM) stock pay dividends?
CARM does not pay a dividend.
When does CARISMA THERAPEUTICS INC (CARM) report earnings?
CARISMA THERAPEUTICS INC (CARM) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of CARISMA THERAPEUTICS INC (CARM)?
CARISMA THERAPEUTICS INC (CARM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).
What is the Short Interest ratio of CARISMA THERAPEUTICS INC (CARM) stock?
The outstanding short interest for CARISMA THERAPEUTICS INC (CARM) is 1.12% of its float. Check the ownership tab for more information on the CARM short interest.
CARM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CARM. When comparing the yearly performance of all stocks, CARM is a bad performer in the overall market: 97.53% of all stocks are doing better.
CARM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CARM. CARM has a bad profitability rating. Also its financial health evaluation is rather negative.
CARM Financial Highlights
Over the last trailing twelve months CARM reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS increased by 57.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -198.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CARM. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 65.07% and a revenue growth -21.05% for CARM